AlphAIAlphAI — Financial news for AI agents
insidermonkey.comOCT 42 min read$ADM

Archer-Daniels Stock is Trading at 15 Times Forward Earnings. Is that Cheap?

Archer-Daniels-Midland (ADM) stock has risen 32% this year, with earnings recovering. Q2 2026 saw operating profit increases across segments. ADM trades at 15x forward earnings, raised from guidance. Its scale and dividend history support valuation, but peers trade cheaper. Future earnings depend on biofuel, energy, and trade policies.

Original reporting
insidermonkey.com
Published Oct 4, 2026, 11:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 2:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Archer-Daniels Stock is Trading at 15 Times Forward Earnings. Is that Cheap? — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$ADMNeutralLow
01

Why it matters

The analysis does not introduce new data, so trading impact is limited to valuation perception.

02

Market read

Provides a valuation perspective on ADM after its earnings recovery, but no fresh catalyst.

03

What to watch

Potential upside from biofuel demand and nutrition segment growth could justify the premium.

Relevance 4/10Novelty 2/10Timing: post‑earnings period

Background

ADM reported Q2 2026 results and raised its 2026 EPS guidance; the article revisits valuation metrics.

Company-level read

Ticker impact

$ADMNeutralMedium confidence
Context

Article evaluates ADM's forward P/E valuation and dividend after earnings recovery, but provides no new corporate data.

Expected impact

potential downside as market may price in slower earnings recovery

Evidence & confidence

The piece is a recap of already‑public earnings and guidance, offering only valuation commentary.

Market effects

Sector

Highlights that agribusiness peers may trade at lower multiples, but no direct sector shift.

Regional

U.S. agribusiness investors may reassess ADM relative to peers.

Global

Limited; focuses on a single U.S. company.

Counterpoint

What could challenge this read

Some investors may see the 15x forward multiple as still attractive given ADM's scale and dividend.

Key entities

  • company
    Archer-Daniels-Midland Company

    U.S. agribusiness firm (ticker ADM).

Read at source← All news

Related articles

OCT 5
$ADMMed

CJ CheilJedang partners with ADM to boost U.S. lysine output amid China curbs

CJ CheilJedang (097950) and ADM formed a joint venture to boost U.S. lysine production, with CJ holding a 63% stake. The move aims to compete with Chinese lysine amid tightened trade restrictions. CJ will contribute its U.S. and Brazil facilities, while ADM will provide its Illinois plant and raw material network. Lysine prices have rebounded due to trade actions against China, with U.S. prices up 38% since December.

biz.chosun.com2 min
OCT 3
$ADMMed

Amino Acids Venture Might Change The Case For Investing In ADM Stock

Archer-Daniels-Midland (ADM) and CJ CheilJedang formed a joint venture to produce and sell feed-grade amino acids in the Americas. The deal, with CJ as majority owner, includes ADM's Decatur facility. Analysts expect ADM's revenue to grow 2.8% annually to $89.2B by 2029, with earnings rising to $2.3B. The joint venture is part of ADM's broader strategy to focus on fermentation-based offerings and animal nutrition.

simplywall.st3 min
OCT 2
$ADMMedAI 8/10

CJ CheilJedang and ADM form amino acid joint venture

CJ CheilJedang (KRX:097950) and ADM (NYSE:ADM) agreed to form a joint venture to produce and market feed-grade amino acids in the Americas. CJ will license its technology and hold majority ownership. The venture will use facilities in Iowa, Illinois, and Brazil, aiming to enhance cost competitiveness and support U.S. production.

investing.com2 min
SEP 25
$ADMMed

ADM’s Infant Probiotic Trial: A New Data Catalyst In Consumer Health

Archer-Daniels-Midland (ADM) completed a clinical trial testing a probiotic for infant colic relief. The double-blinded, placebo-controlled study aims to support ADM's position in science-backed nutrition. Positive results could boost ADM's pediatric nutrition sales and stock sentiment. The trial was updated on September 22, 2026, with data analysis underway.

tipranks.com1 min
SEP 15
$CNCMed

2 Non-AI Giants to Buy on Solid Guidance and Lucrative Valuation

Centene Corp. (CNC) and Archer-Daniels-Midland Co. (ADM) are highlighted for strong performance and attractive valuations. CNC expects 2026 revenues of $173-$177B and adjusted EPS over $4.80, with a forward P/E of 13.58X. ADM raised 2026 adjusted earnings guidance to $5.15-$5.60 per share, with a forward P/E of 16.60X.

tradingview.com3 min